Results 91 to 100 of about 321,312 (283)

Widespread intronic polyadenylation diversifies immune cell transcriptomes

Nature Communications, 2018
Recognition of intronic polyadenylation (IpA) signals can lead to expression of truncated proteins lacking C terminal domains. Analysis of 3ʹ -seq and RNA-seq shows that IpA is widespread in circulating immune cells, while multiple myeloma cells show ...
Irtisha Singh, Shih-Han Lee, Adam S. Sperling, Mehmet K. Samur, Yu-Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Christine Mayr, Christina S. Leslie   +8 more
doaj   +1 more source

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

BMC Cancer, 2018
Background Multiple myeloma (MM) patients with t(14;20) have a poor prognosis and their outcome has not improved following the introduction of bortezomib (Bzb).
Ya-Wei Qiang, Shiqiao Ye, Yuhua Huang, Yu Chen, Frits Van Rhee, Joshua Epstein, Brian A. Walker, Gareth J. Morgan, Faith E. Davies   +8 more
doaj   +1 more source

HLXB9 gene expression, and nuclear location during in vitro neuronal differentiation in the SK-N-BE neuroblastoma cell line [PDF]

, 2014
Copyright @ 2014 Leotta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source ...
Brundo, MV, Federico, C, Leotta, CG, Saccone, S, Tosi, S   +4 more
core   +1 more source

Epidemiology of Cancer‐Associated Venous Thromboembolism Across the United States

American Journal of Hematology, EarlyView.
ABSTRACT Prior epidemiological studies on cancer‐associated venous thromboembolism (VTE) were limited by homogenous patient populations. We leverage Cosmos, a collaborative dataset of Epic electronic health record systems, to conduct an updated evaluation of cancer‐associated VTE in the United States (US).
Barbara D. Lam, Justine Ryu, Omid Jafari, Rock Bum Kim, Shengling Ma, Mrinal Ranjan, Jun Y. Jiang, Ang Li   +7 more
wiley   +1 more source

The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells _in vitro_ and _in vivo_ [PDF]

, 2008
CD138 (Syndecan1) is highly expressed on multiple myeloma (MM) cells. In this study, we examined the anti-MM effect of murine/human chimeric CD138-specific monoclonal antibody (mAb) nBT062 conjugated with highly cytotoxic maytansinoid derivatives _in ...
Benjamin Dä, Christoph Uherek, Diana Cristea, Frank Osterroth, Giulia Perrone, Hiroshi Ikeda, Hiroshi Yasui, Kenneth C. Anderson, Loredana Santo, Mariateresa Fulciniti, Nikhil C. Munshi, Noopur S. Raje, Paul Richardson, Robert J. Lutz, Samantha Pozzi, Silkie Aigner, Sonia Vallet, Tanyel Kiziltepe, Teru Hideshima, Yu-Tzu Tai, Yutaka Okawa   +20 more
core   +1 more source

The RAG Model: a new paradigm for genetic risk stratification in multiple myeloma [PDF]

, 2014
Molecular studies have shown that multiple myeloma is a highly genetically heterogonous disease which may manifest itself as any number of diverse subtypes each with variable clinicopathological features and outcomes.
Chevassut, Timothy J, Conway O'Brien, Emma, Prideaux, Steven M   +2 more
core   +3 more sources

Navigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz, Winfried Alsdorf, Lisa Leypoldt, Piet Sonnemann, Christoph Schaefers, Jule Artzenroth, Marie Harzer, Abdulaziz Kamili, Leandra Bartke, Leon Cords, Jan Vorwerk, Theo Leitner, Markus Maulhardt, Kerstin Brinkert, Annamaria Brioli, Tim Richardson, Udo Holtick, Stefan M. Hillmann, Hans Salwender, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Ricardo Kosch   +22 more
wiley   +1 more source

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma

Haematologica, 2013
Relapsed/refractory multiple myeloma represents a major challenge in multiple myeloma therapy. For patients with relapsed/refractory multiple myeloma, we developed a treatment schema of metronomically scheduled drug therapy.
Xenofon Papanikolaou, Jackie Szymonifka, Adam Rosenthal, Christoph J. Heuck, Alan Mitchell, Donald Johann, Jason Keller, Sarah Waheed, Saad Z. Usmani, Frits Van Rhee, Clyde Bailey, Nathan Petty, Antje Hoering, John Crowley, Bart Barlogie   +14 more
doaj   +1 more source

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review

American Journal of Hematology, EarlyView.
ABSTRACT Renal impairment (RI), defined as estimated glomerular filtration rate less than 60 mL/min with or without the need for dialysis, is a frequent and severe complication in patients with relapsed/refractory multiple myeloma (RRMM), as it can affect patient prognosis, drug metabolism and treatment options.
Ioannis Ntanasis‐Stathopoulos, Sotirios Manganas, Charalampos Filippatos, Konstantinos Karamouzis, Maria Gavriatopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios‐Athanasios Dimopoulos   +7 more
wiley   +1 more source

Mapping Functions in Health-Related Quality of Life: Mapping From Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L. [PDF]

, 2015
BACKGROUND: Clinical trials in cancer frequently include cancer-specific measures of health but not preference-based measures such as the EQ-5D that are suitable for economic evaluation.
Brazier, JE, Longworth, L, Mukuria, C, Rowen, D, Young, TA   +4 more
core   +2 more sources